Literature DB >> 16720085

Simultaneous modulation of transport and metabolism of acyclovir prodrugs across rabbit cornea: An approach involving enzyme inhibitors.

Suresh Katragadda1, Ravi S Talluri, Ashim K Mitra.   

Abstract

The aim of this study is to identify the class of enzymes responsible for the hydrolysis of amino acid and dipeptide prodrugs of acyclovir (ACV) and to modulate transport and metabolism of amino acid and dipeptide prodrugs of acyclovir by enzyme inhibitors across rabbit cornea. l-Valine ester of acyclovir, valacyclovir (VACV) and l-glycine-valine ester of acyclovir, gly-val-acyclovir (GVACV) were used as model compounds. Hydrolysis studies of VACV and GVACV in corneal homogenate were conducted in presence of various enzyme inhibitors. IC(50) values were determined for the enzyme inhibitors. Transport studies were conducted with isolated rabbit corneas at 34 degrees C. Complete inhibition of VACV hydrolysis was observed in the presence of Pefabloc SC (4-(2-aminoethyl)-benzenesulfonyl-fluoride) and PCMB (p-chloromercuribenzoic acid). Similar trend was also observed with GVACV in the presence of bestatin. IC(50) values of PCMB and bestatin for VACV and GVACV were found to be 3.81+/-0.94 and 0.34+/-0.08muM respectively. Eserine, tetraethyl pyrophosphate (TEPP) and diisopropyl fluorophosphate (DFP) also produced significant inhibition of VACV hydrolysis. Transport of VACV and GVACV across cornea showed decreased metabolic rate and modulation of transport in presence of PCMB and bestain respectively. The principle enzyme classes responsible for the hydrolysis of VACV and GVACV were carboxylesterases and aminopeptidases respectively. Enzyme inhibitors modulated the transport and metabolism of prodrugs simultaneously even though their affinity towards prodrugs was distinct. In conclusion, utility of enzyme inhibitors to modulate transport and metabolism of prodrugs appears to be promising strategy for enhancing drug transport across cornea.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16720085     DOI: 10.1016/j.ijpharm.2006.04.010

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  4 in total

Review 1.  Phase I and phase II ocular metabolic activities and the role of metabolism in ophthalmic prodrug and codrug design and delivery.

Authors:  Abeer M Al-Ghananeem; Peter A Crooks
Journal:  Molecules       Date:  2007-03-08       Impact factor: 4.411

2.  Novel biotinylated lipid prodrugs of acyclovir for the treatment of herpetic keratitis (HK): transporter recognition, tissue stability and antiviral activity.

Authors:  Aswani Dutt Vadlapudi; Ramya Krishna Vadlapatla; Ravinder Earla; Suman Sirimulla; Jake Brain Bailey; Dhananjay Pal; Ashim K Mitra
Journal:  Pharm Res       Date:  2013-05-09       Impact factor: 4.200

3.  Synthesis, metabolism and cellular permeability of enzymatically stable dipeptide prodrugs of acyclovir.

Authors:  Ravi S Talluri; Swapan K Samanta; Ripal Gaudana; Ashim K Mitra
Journal:  Int J Pharm       Date:  2008-06-23       Impact factor: 5.875

4.  Potential pharmacokinetic role of organic cation transporters in modulating the transcorneal penetration of its substrates administered topically.

Authors:  J Nirmal; S B Singh; N R Biswas; V Thavaraj; R V Azad; T Velpandian
Journal:  Eye (Lond)       Date:  2013-07-12       Impact factor: 3.775

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.